
Galectin Therapeutics Inc.: stock overview
Price
$2.69
November 20, 2026Market cap $271M
What Ploutos Investor adds for Galectin Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 16 fiscal years, from 2010
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
In short
It pays no dividend.
From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 20, 2026.
Its SEC filings- Market cap
- $271M
- 101M shares
- P/E
- –
- Revenue, 12 months
- –
- Net margin
- –
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
Fiscal years in figures
GALT's revenue, profit, cash flow and dividend with each year-end price, from 2010 to 2022, 13 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap 3-year median: $103M
- $271M
- Enterprise value
- –
- P/E
- –
- EV / EBIT
- –
- EV / Revenue
- –
- P/B
- –
- FCF yield
- –
- Earnings yield 3-year median: -44.6%
- –
Profitability
Sorry, we do not have enough data
for the “Profitability” group
Growth
Sorry, we do not have enough data
for the “Growth” group
Balance sheet
- Cash
- $12M
- Total debt
- –
- Net cash
- –
- Net debt / EBITDA
- –
- Interest cover
- -3.0x
- Current ratio
- 0.28
Balance sheet of September 30, 2026.
Returns to shareholders
- Dividend yield
- 0.00%
- Buybacks
- –
- Total returned
- 0.00%
- Shares, yearly change
- +4.2%
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- GALECTIN THERAPEUTICS INC
- CIK
- 1133416
- Exchange
- NASDAQ
- Industry (SIC)
- 2834 · Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Latest annual report
- December 31, 2025
- Reporting currency
- USD
- Shares
- 101M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with GALT
- JNJJohnson & Johnson+0,00%Compare with GALT
- ABBVAbbVie+0,00%Compare with GALT
- UNHUnitedHealth+0,00%Compare with GALT
- MRKMerck & Company+0,00%Compare with GALT
- AMGNAmgen+0,00%Compare with GALT
- TMOThermo Fisher Scientific+0,00%Compare with GALT
- ABTAbbott Laboratories+0,00%Compare with GALT
The full analysis
What do Galectin Therapeutics's filings show?
These are Galectin Therapeutics's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is GALT's market cap?
Galectin Therapeutics Inc.'s market cap is $271M, at a price of $2.69 on November 20, 2026 and 101M shares.
Does GALT pay a dividend?
No. Galectin Therapeutics paid no regular dividend over the last 12 months.
Where do the figures come from?
From Galectin Therapeutics Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.